keyword
MENU ▼
Read by QxMD icon Read
search

Tau and PET

keyword
https://www.readbyqxmd.com/read/28612291/-f-18-av-1451-binding-correlates-with-postmortem-neurofibrillary-tangle-braak-staging
#1
Marta Marquié, Michael Siao Tick Chong, Alejandro Antón-Fernández, Eline E Verwer, Nil Sáez-Calveras, Avery C Meltzer, Prianca Ramanan, Ana C Amaral, Jose Gonzalez, Marc D Normandin, Matthew P Frosch, Teresa Gómez-Isla
[F-18]-AV-1451, a PET tracer specifically developed to detect brain neurofibrillary tau pathology, has the potential to facilitate accurate diagnosis of Alzheimer's disease (AD), staging of brain tau burden and monitoring disease progression. Recent PET studies show that patients with mild cognitive impairment and AD dementia exhibit significantly higher in vivo [F-18]-AV-1451 retention than cognitively normal controls. Importantly, PET patterns of [F-18]-AV-1451 correlate well with disease severity and seem to match the predicted topographic Braak staging of neurofibrillary tangles (NFTs) in AD, although this awaits confirmation...
June 13, 2017: Acta Neuropathologica
https://www.readbyqxmd.com/read/28587897/comparison-of-multiple-tau-pet-measures-as-biomarkers-in-aging-and-alzheimer-s-disease
#2
Anne Maass, Susan Landau, Suzanne L Baker, Andy Horng, Samuel N Lockhart, Renaud La Joie, Gil D Rabinovici, William J Jagust
The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal...
June 3, 2017: NeuroImage
https://www.readbyqxmd.com/read/28584971/f-18-fdg-and-f-18-tau-pet-in-posterior-cortical-atrophy
#3
Madhavi Tripathi, Abhinav Bansal, Vivek Baghel, Praveen Kumar, Chandrasekhar Bal
No abstract text is available yet for this article.
June 6, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28583275/benign-cutaneous-and-subcutaneous-lesions-on-fdg-pet-ct
#4
REVIEW
Ur Metser, Noam Tau
(18)F-FDG, the most commonly used PET radiopharmaceutical in clinical practice, can also accumulate in inflammatory and infectious conditions. This may account for false-positive PET findings when staging or restaging a patient with malignancy. As clinical use of FDG-PET-CT is increasing, nuclear medicine physicians are encountering a myriad of cutaneous and subcutaneous lesions, many of which are incidental and benign. The most common cause for the FDG avidity of these lesions is inflammation. Although a specific diagnosis may not always be possible, background clinical history and morphologic features of the lesion on CT may help narrow the differential diagnosis...
July 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/28576172/multimodal-pet-imaging-of-amyloid-and-tau-pathology-in-alzheimer-disease-and-non-alzheimer-disease-dementias
#5
REVIEW
Chenjie Xia, Bradford C Dickerson
Biomarkers of the molecular pathology underpinning dementia syndromes are increasingly recognized as crucial for diagnosis and development of disease-modifying treatments. Amyloid PET imaging is an integral part of the diagnostic assessment of Alzheimer disease. Its use has also deepened understanding of the role of amyloid pathology in Lewy body disorders and aging. Tau PET imaging is an imaging biomarker that will likely play an important role in the diagnosis, monitoring, and treatment in dementias. Using tau PET imaging to examine how tau pathology relates to amyloid and other markers of neurodegeneration will serve to better understand the pathophysiologic cascade that leads to dementia...
July 2017: PET Clinics
https://www.readbyqxmd.com/read/28576171/pet-imaging-for-early-detection-of-alzheimer-s-disease-from-pathologic-to-physiologic-biomarkers
#6
REVIEW
Weiqi Bao, Hongmei Jia, Sjoerd Finnema, Zhengxin Cai, Richard E Carson, Yiyun Henry Huang
This article describes the application of various PET imaging agents in the investigation and diagnosis of Alzheimer's disease (AD), including radiotracers for pathologic biomarkers of AD such as β-amyloid deposits and tau protein aggregates, and the neuroinflammation biomarker 18 kDa translocator protein, as well as physiologic biomarkers, such as cholinergic receptors, glucose metabolism, and the synaptic density biomarker synaptic vesicle glycoprotein 2A. Potential of these biomarkers for early AD diagnosis is also assessed...
July 2017: PET Clinics
https://www.readbyqxmd.com/read/28568506/pbb3-imaging-in-parkinsonian-disorders-evidence-for-binding-to-tau-and-other-proteins
#7
Alexandra Perez-Soriano, Julieta E Arena, Katie Dinelle, Qing Miao, Jessamyn McKenzie, Nicole Neilson, Andreas Puschmann, Paul Schaffer, Hitoshi Shinotoh, Jenna Smith-Forrester, Elham Shahinfard, Nasim Vafai, Daryl Wile, Zbigniew Wszolek, Makoto Higuchi, Vesna Sossi, A Jon Stoessl
BACKGROUND AND OBJECTIVES: To study selective regional binding for tau pathology in vivo, using PET with [(11) C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy. METHODS: Dynamic PET scans were obtained for 70 minutes after the bolus injection of [(11) C]PBB3 in 5 PSP subjects, 1 subject with DCTN1 mutation and PSP phenotype, 3 asymptomatic SNCA duplication carriers, 1 MSA subject, and 6 healthy controls of similar age. Tissue reference Logan analysis was applied to each region of interest using a cerebellar white matter reference region...
June 1, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28558094/hierarchical-organization-of-tau-and-amyloid-deposits-in-the-cerebral-cortex
#8
Jorge Sepulcre, Michel J Grothe, Mert Sabuncu, Jasmeer Chhatwal, Aaron P Schultz, Bernard Hanseeuw, Georges El Fakhri, Reisa Sperling, Keith A Johnson
Importance: Abnormal accumulation of tau and amyloid-β (Aβ) proteins in the human brain are 2 pathologic hallmarks of Alzheimer disease (AD). Because pathologic processes begin decades before the onset of the clinical manifestations, the study of the cortical distribution of early-stage pathologic alterations is critical in understanding the underpinnings of the disease. Objectives: To identify the in vivo brain spatial distributions of tau and Aβ deposits in a sample of cognitively normal participants in the Harvard Aging Brain Study, determine spatial patterns of pathologic alterations, and provide means for improved individual in vivo staging...
May 30, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28545932/the-association-between-tau-pet-and-retrospective-cortical-thinning-in-clinically-normal-elderly
#9
Molly R LaPoint, Jasmeer P Chhatwal, Jorge Sepulcre, Keith A Johnson, Reisa A Sperling, Aaron P Schultz
Tau pathology has been associated with neuronal loss at autopsy, but the temporal evolution of tau pathology and atrophy remains unclear. Here, we investigate the association between cross-sectional AV-1451-PET as a marker of tau pathology and cortical thickness cross-sectionally. We also investigated retrospective rates of cortical thinning over the three years preceding the AV-1451 scan in a clinically normal cohort of 103 older adults from the Harvard Aging Brain Study. Tau measurements were Geometric Transfer Matrix partial volume corrected standardized uptake value ratios (SUVRs) with a cerebellar grey reference region...
May 22, 2017: NeuroImage
https://www.readbyqxmd.com/read/28507319/longitudinal-changes-of-tau-pet-imaging-in-relation-to-hypometabolism-in-prodromal-and-alzheimer-s-disease-dementia
#10
K Chiotis, L Saint-Aubert, E Rodriguez-Vieitez, A Leuzy, O Almkvist, I Savitcheva, M Jonasson, M Lubberink, A Wall, G Antoni, A Nordberg
The development of tau-specific positron emission tomography (PET) tracers allows imaging in vivo the regional load of tau pathology in Alzheimer's disease (AD) and other tauopathies. Eighteen patients with baseline investigations enroled in a 17-month follow-up study, including 16 with AD (10 had mild cognitive impairment and a positive amyloid PET scan, that is, prodromal AD, and six had AD dementia) and two with corticobasal syndrome. All patients underwent PET scans with [(18)F]THK5317 (tau deposition) and [(18)F]FDG (glucose metabolism) at baseline and follow-up, neuropsychological assessment at baseline and follow-up and a scan with [(11)C]PIB (amyloid-β deposition) at baseline only...
May 16, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28500751/radiological-biomarkers-for-diagnosis-in-psp-where-are-we-and-where-do-we-need-to-be
#11
REVIEW
Jennifer L Whitwell, Günter U Höglinger, Angelo Antonini, Yvette Bordelon, Adam L Boxer, Carlo Colosimo, Thilo van Eimeren, Lawrence I Golbe, Jan Kassubek, Carolin Kurz, Irene Litvan, Alexander Pantelyat, Gil Rabinovici, Gesine Respondek, Axel Rominger, James B Rowe, Maria Stamelou, Keith A Josephs
BACKGROUND: PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. Our aim was to critically evaluate the degree to which structural, functional and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. METHODS: We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English using postmortem diagnosis or NINDS-SPSP criteria as the diagnostic standard from 1996-2016...
May 13, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28487650/neuropsychological-testing-and-machine-learning-distinguish-alzheimer-s-disease-from-other-causes-for-cognitive-impairment
#12
Pavel Gurevich, Hannes Stuke, Andreas Kastrup, Heiner Stuke, Helmut Hildebrandt
With promising results in recent treatment trials for Alzheimer's disease (AD), it becomes increasingly important to distinguish AD at early stages from other causes for cognitive impairment. However, existing diagnostic methods are either invasive (lumbar punctures, PET) or inaccurate Magnetic Resonance Imaging (MRI). This study investigates the potential of neuropsychological testing (NPT) to specifically identify those patients with possible AD among a sample of 158 patients with Mild Cognitive Impairment (MCI) or dementia for various causes...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28456479/age-specific-and-sex-specific-prevalence-of-cerebral-%C3%AE-amyloidosis-tauopathy-and-neurodegeneration-in-cognitively-unimpaired-individuals-aged-50-95-years-a-cross-sectional-study
#13
Clifford R Jack, Heather J Wiste, Stephen D Weigand, Terry M Therneau, David S Knopman, Val Lowe, Prashanthi Vemuri, Michelle M Mielke, Rosebud O Roberts, Mary M Machulda, Matthew L Senjem, Jeffrey L Gunter, Walter A Rocca, Ronald C Petersen
BACKGROUND: A new classification for biomarkers in Alzheimer's disease and cognitive ageing research is based on grouping the markers into three categories: amyloid deposition (A), tauopathy (T), and neurodegeneration or neuronal injury (N). Dichotomising these biomarkers as normal or abnormal results in eight possible profiles. We determined the clinical characteristics and prevalence of each ATN profile in cognitively unimpaired individuals aged 50 years and older. METHODS: All participants were in the Mayo Clinic Study of Aging, a population-based study that uses a medical records linkage system to enumerate all individuals aged 50-89 years in Olmsted County, MN, USA...
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28441967/comparison-of-csf-markers-and-semi-quantitative-amyloid-pet-in-alzheimer-s-disease-diagnosis-and-in-cognitive-impairment-prognosis-using-the-adni-2-database
#14
Fayçal Ben Bouallègue, Denis Mariano-Goulart, Pierre Payoux
BACKGROUND: The relative performance of semi-quantitative amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) markers in diagnosing Alzheimer's disease (AD) and predicting the cognitive evolution of patients with mild cognitive impairment (MCI) is still debated. METHODS: Subjects from the Alzheimer's Disease Neuroimaging Initiative 2 with complete baseline cognitive assessment (Mini Mental State Examination, Clinical Dementia Rating [CDR] and Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-cog] scores), CSF collection (amyloid-β1-42 [Aβ], tau and phosphorylated tau) and (18)F-florbetapir scans were included in our cross-sectional cohort...
April 26, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28440890/fluorescence-and-autoradiographic-evaluation-of-tau-pet-ligand-pbb3-to-%C3%AE-synuclein-pathology
#15
Shunsuke Koga, Maiko Ono, Naruhiko Sahara, Makoto Higuchi, Dennis W Dickson
BACKGROUND: The tau PET ligand 2-((1E,3E)-4-(6-([(11) C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([(11) C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [(11) C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. METHOD: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden...
April 25, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28422821/how-the-cognitive-reserve-interacts-with-%C3%AE-amyloid-deposition-in-mitigating-fdg-metabolism-an-observational-study
#16
Elena Carapelle, Laura Serra, Sergio Modoni, Michele Falcone, Carlo Caltagirone, Marco Bozzali, Luigi Maria Specchio, Carlo Avolio
This observational study had the aim to assess the interaction between cognitive reserve (CR) and cerebrospinal fluid β-amyloid1-42 (Aβ1-42) in modulating brain [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) metabolism in patients with moderate Alzheimer disease (AD).Twenty-seven patients with probable AD and 25 neurological normal subjects (NNS) entered the study. All participants had an FDG-PET scan, and AD patients also received a lumbar puncture to measure Aβ1-42, 181p-tau, and Tau concentrations...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28415771/11c-choline-pet-ct-and-whole-body-mri-including-diffusion-weighted-imaging-for-patients-with-recurrent-prostate-cancer
#17
Hinrich Wieder, Ambros J Beer, Konstantin Holzapfel, Martin Henninger, Tobias Maurer, Sarah Schwarzenboeck, Ernst J Rummeny, Matthias Eiber, Jens Stollfuss
PURPOSE: To compare the detection efficacy of 11C-choline positron emission tomography and computed tomography (PET/CT) with whole-body magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) in patients with suspected recurrent prostate cancer. MATERIAL AND METHODS: Fifty-seven patients (mean age 68, range 54-80 years) underwent 11C-choline PET/CT and MRI using T1-weighted (T1w), short-tau inversion recovery (STIR), and DWI. Two readers visually rated suspicious lesions on a 5-point scale in 20 different regions...
March 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408865/tau-pathology-distribution-in-alzheimer-s-disease-corresponds-differentially-to-cognition-relevant-functional-brain-networks
#18
Oskar Hansson, Michel J Grothe, Tor Olof Strandberg, Tomas Ohlsson, Douglas Hägerström, Jonas Jögi, Ruben Smith, Michael Schöll
Neuropathological studies have shown that the typical neurofibrillary pathology of hyperphosphorylated tau protein in Alzheimer's disease (AD) preferentially affects specific brain regions whereas others remain relatively spared. It has been suggested that the distinct regional distribution profile of tau pathology in AD may be a consequence of the intrinsic network structure of the human brain. The spatially distributed brain regions that are most affected by the spread of tau pathology may hence reflect an interconnected neuronal system...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28404803/neuropsychiatric-symptoms-predict-hypometabolism-in-preclinical-alzheimer-disease
#19
Kok Pin Ng, Tharick A Pascoal, Sulantha Mathotaarachchi, Chang-Oh Chung, Andréa L Benedet, Monica Shin, Min Su Kang, Xiaofeng Li, Maowen Ba, Nagaendran Kandiah, Pedro Rosa-Neto, Serge Gauthier
OBJECTIVE: To identify regional brain metabolic dysfunctions associated with neuropsychiatric symptoms (NPS) in preclinical Alzheimer disease (AD). METHODS: We stratified 115 cognitively normal individuals into preclinical AD (both amyloid and tau pathologies present), asymptomatic at risk for AD (either amyloid or tau pathology present), or healthy controls (no amyloid or tau pathology present) using [(18)F]florbetapir PET and CSF phosphorylated tau biomarkers...
May 9, 2017: Neurology
https://www.readbyqxmd.com/read/28394771/tau-pet-binding-distinguishes-patients-with-early-stage-posterior-cortical-atrophy-from-amnestic-alzheimer-disease-dementia
#20
Gregory S Day, Brian A Gordon, Kelley Jackson, Jon J Christensen, Maria Rosana Ponisio, Yi Su, Beau M Ances, Tammie L S Benzinger, John C Morris
BACKGROUND: Flortaucipir (tau) positron emission tomography (PET) binding distinguishes individuals with clinically well-established posterior cortical atrophy (PCA) due to Alzheimer disease (AD) from cognitively normal (CN) controls. However, it is not known whether tau-PET binding patterns differentiate individuals with PCA from those with amnestic AD, particularly early in the symptomatic stages of disease. METHODS: Flortaucipir and florbetapir (β-amyloid) PET imaging were performed in individuals with early-stage PCA (N=5), amnestic AD dementia (N=22), and CN controls (N=47)...
April 2017: Alzheimer Disease and Associated Disorders
keyword
keyword
114281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"